Treating colorectal cancer with a whole, leech saliva extract

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Biopep Solutions, Inc. patent solves the following problem:

The teachings given here are generally directed to methods of isolating and using a whole-leech saliva taken for the treatment of a subject.

Our analysis of this patent is as follows:

Biopep Solutions, Inc.’s patent US 9265802 B2 deals with Treating colorectal cancer with a whole, leech saliva extract.
Methods are provided for isolating and using a whole-leech saliva taken. The method may include feeding a phagostimulatory agent a leech; force a regurgitation of leeches, the force including putting leeches in an environment with a temperature of less than about 0 C.; and, collecting an unrefined, whole saliva regurgitation cooled leeches. The methods may include enhancing the leech by warming it to a temperature of about 5 C. to 40 C. Stable, lyophilized, whole-saliva extracts a leech also given, taken with a strong activity when stored for use at a temperature below 20 C., took to maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treatment of liquid tumors, treating diabetes, treating a viral disease, treat a parasitic disease, treated with an antibacterial diseases, or to serve as an anti-oxidant.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Treating a melanoma with a whole, leech saliva extract

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Biopep Solutions, Inc. patent solves the following problem:

The teachings given here are generally directed to methods of isolating and using a whole-leech saliva taken for the treatment of a subject.

Our analysis of this patent is as follows:

Biopep Solutions, Inc.’s patent US 9265803 B2 deals with Treating a melanoma with a whole, leech saliva extract.
Methods also provided for isolating and using a whole-leech saliva taken for the treatment of a melanoma. The method may include feeding a phagostimulatory agent a leech; force a regurgitation of leeches, the force including putting leeches in an environment with a temperature of less than about 0 C.; and, collecting an unrefined, whole saliva regurgitation cooled leeches. The methods may include enhancing the leech by warming it to a temperature of about 5 C. to 40 C. Stable, lyophilized, whole-saliva extracts a leech also given, taken with a strong activity when stored for use at a temperature below 20 C., took to maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treatment of liquid tumors, treating diabetes, treating a viral disease, treat a parasitic disease, treated with an antibacterial diseases, or to serve as an anti-oxidant.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Peptides for inducing heterosubtypic influenza T cell responses

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Saint Louis University patent solves the following problem:

The present invention relates to the general fields of virology and immunotherapy. Especially, it is about recognizing the immunostimulatory peptide and the development of peptide vaccines for the treatment and prevention of influenza.

Our analysis of this patent is as follows:

Saint Louis University’s patent US 9265822 B2 deals with Peptides for inducing heterosubtypic influenza T cell responses.
The present invention provides compositions and methods for the generation of an anti-influenza immune response. In particular, conserved T cell epitopes in the protein matrix and nucleoprotein of influenza virus have been identified and further screened for structures that bind two or hľa I and II molecules. Methods for vaccines covered the formulation of the peptide for the treatment or prevention of influenza infaction also described.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Siglec-9 binding agents

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The University Court Of The University Of Dundee patent solves the following problem:

Sialic acid-binding immunoglobulin-like lectins (Siglec ()) is the i-type lectins expressed on a number of cells including cells of the haematopoietic system. Siglecs consists of a number of families of molecules, each characterized by the presence of an A-terminal V-set Ig-like domain, which mediates sialic acid binding, followed by various numbers of C2-set ig-like domains4.

Our analysis of this patent is as follows:

University Court Of The University Of Dundee’s patent US 9265826 B2 deals with Siglec-9 binding agents.
The present invention relates to agents able to bind sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and division disorder. Furthermore, the present invention provides associated pharmaceutical formulations and methods.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-PDGFR-beta antibodies and uses thereof

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Regeneron Pharmaceuticals, Inc. patent solves the following problem:

Platelet-derived growth factors (PDGFs) the potent mitogens that as five different dimeric forms composed of four different isoform subunits: A, B, C and D. the five dimeric form PDGFs AA, BB, AB, CC and DD, who formed the disulfide link corresponding individual PDGF monomers. PDGF ligands exert their biological effects through their interaction with PDGF receptor (PDGFRs). PDGFRs single-pass transmembrane tyrosine kinase receptor composed of heterodimeric or homodimeric association with an alpha () receptor chain (PDGFR-alpha) and / or a beta () receptor chain (PDGFR-beta). Thus, active PDGFRs may contain, or receptor chain pairings. PDGFRs share a common domain structure, including the five extracellular immunoglobulin (Ig) loops, a transmembrane domain, and a split intracellular tyrosine kinase (TK) domain. The interaction between dimeric PDGF ligands and PDGFRs lead to chain receptor dimerization, receptor autophosphorylation and intracellular signal transduction. It has been shown in vitro receptor comes with PDGF-BB and -DD, while the receptor comes in PDGF-BB, CC, -DD and -AB, and receptor come to PDGF-AA, -BB, CC and -AB (see Andrae et al (2008) Gene Dev 22 (10) :. 1276-1312).

Our analysis of this patent is as follows:

Regeneron Pharmaceuticals, Inc.’s patent US 9265827 B2 deals with Anti-PDGFR-beta antibodies and uses thereof.
The present invention provides antibodies that bind to the platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to some embodiments of the invention, the antibody of fully human antibodies that bind to human PDGFR-beta with high affinity. The antibody of the invention is useful for the treatment of diseases and diseases associated with PDGFR-beta signaling and / or PDGFR-beta cellular expression, such as ocular disease, fibrotic disease, vascular disease and cancer.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antagonists of IL-6 to raise albumin and/or lower CRP

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Alderbio Holdings Llc patent solves the following problem:

This creation is an extension of the applicants' prior invention disclosed in the application in the above-referenced patent relates to novel anti-IL-6 antibody and novel therapies and therapeutic protocol using anti-IL-6 antibody, preferably those described here. In particular, this invention relates to methods to improve survivability or quality of life of a patient in need thereof comprising administering to the patient an IL-6 antagonists, where the patient C-reactive protein (CRP ) that the lowered, and / or albumin levels in patients risen.

Our analysis of this patent is as follows:

Alderbio Holdings Llc’s patent US 9265825 B2 deals with Antagonists of IL-6 to raise albumin and/or lower CRP.
The present invention is directed to therapeutic methods of using IL-6 antagonists such as antibody fragments with binding specificity to IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibody can be humanized and / or aglycosylated. Also, in preferred embodiments of these patients involves the exercise (or at risk of developing) a high serum C-reactive protein levels or a decrease in serum albumin levels prior to treatment. In another respect, the patient Glasgow prognostic Score grew and survivability best improved.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for cloning and manipulating genomes

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Synthetic Genomics, Inc. patent solves the following problem:

The use of old organisms genetic systems like the host of nucleic acid molecules isolated from a variety of species that allows for manipulation of the isolated nucleic acid sequences into the host. The ability to engineer organisms by cloning and modification chromosome genomes in exogenous hosts limited, however, by the size limit on the nucleic acid molecule to be transferred to the genus like yeast that a tractable genetics.

Our analysis of this patent is as follows:

Synthetic Genomics, Inc.’s patent US 9267132 B2 deals with Methods for cloning and manipulating genomes.
Composition and method disclosed here for the cloning of an artificial or a semi-synthetic donor genome in a heterologous host cell. In one embodiment, the donor genome may be further modified in a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred into a recipient cell. Methods disclosed here can be used again in donor genomes from chastened donor cells more tractable host cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods of modulating MicroRNAs in the treatment of pulmonary arterial hypertension

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The The University Court Of The University Of Glasgow, , Cambridge Enterprise Limited patent solves the following problem:

Pulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries (PAs), characterized by an increase in PA pressure and vascular remodeling leading to a progressive increase in pulmonary vascular resistance (Rich et al. , 1987). The consequences of vascular destruction right in heart failure and high mortality (Jeffery et al, 2002. Voelkel et al, 1997). Germline mutations in the gene coding for bone morphogenetic protein (BMP) type-2 receptor (BMPR2), a receptor for transforming growth factor (TGF) – super-family, identified in approximately 70% patients with heritable forms of pAH (hPAH) (Morrell et al., 2001). Furthermore, BMPR2 expression also markedly reduced pah cases without mutations in this gene (idiopathic PAH, ipah), suggesting a broader role for this receptor pathway of development pah. In pulmonary artery smooth muscle cells (PASMCs) mutations in BMPR2 associated with an abnormal growth response to BMPs and TGF-. In endothelial cells, these mutations increase susceptibility of cells to apoptosis (PAECs) (Morrell et al., 2001). The loss BMPR2 mutations in some families and in most ipah cases suggests that further pathological mechanisms, likely related to TGF- super-family, still to be identified.

Our analysis of this patent is as follows:

The University Court Of The University Of Glasgow, , Cambridge Enterprise Limited’s patent US 9267134 B2 deals with Methods of modulating MicroRNAs in the treatment of pulmonary arterial hypertension.
The present invention provides a method of treating or preventing pulmonary hypertension in a subject in need thereof by administering to the subject an inhibitor of miR-145 expression or activity. Pharmaceutical compositions and kits comprising miR-145 inhibitor for treating pulmonary hypertension is also disclosed.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Mass spectrometric methods for quantifying NPY 1-36 and NPY 3-36

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Georgetown University patent solves the following problem:

Neuropeptide Y (NPY) is a 36-amino acid peptide neurotransmitter found in the brain and the autonomic nervous system; it is the most abundant neuropeptide in serum and plasma. NPY 1-36 in association with a number of physiological processes in the brain, including the regulation of energy balance, memory and learning, and epilepsy. The first effect of NPY increased food and decreased physical activity. NPY 1-36 hidden in the hypothalamus, and, in addition to increasing food, it increases the amount of energy stored as fat and blocks nociceptive signals to the brain. Important, NPY 1-36 increased vasoconstrictor effects of noradrenergic neurons. The entire peptide, therefore, an important diagnostic in patients suffering from hypertension, stress, and heart disease, for example.

Our analysis of this patent is as follows:

Georgetown University’s patent US 9269550 B2 deals with Mass spectrometric methods for quantifying NPY 1-36 and NPY 3-36.
If the methods of detecting the presence or amount of NPY 1-36 NPY 3-36 in a sample using mass spectrometry. Important, by the way of creation, the NPY 1-36 NPY 3-36 can be quantified simultaneously, separately and independently of a sample consisting of two peptide. The methods provide enhanced specificity, and excellent sense of the limit of quantitation (LOQ) of 0.1 ng / ml, and done in less time and with less sample preparation than that of the other Explore the NPY. In some embodiments, because the methods of the invention is specific for NPY 1-36 NPY 3-36, the way to give a major advantage over current immunoassays. Therefore, the method can be used to obtain reliable data on the concentration of some important patient populations, such as patients with hypertension, heart disease, or cancer.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Neurological stimulation lead anchors and associated systems and methods

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Nevro Corporation patent solves the following problem:

Neurological stimulators developed to treat pain, movement disorders, functional disorders, spasticity, cancer, heart disorders, and various medical conditions. Implantable neurological stimulation system usually has an Implantable signal generator and one or more leads that deliver electrical pulses to the brain or muscle tissue. For example, certain neurological stimulation system in a cylindrical lead includes a lead body with a circular cross-sectional shape and one or more conductive rings (ie, contacts) spaced apart from each other in distal end of the lead body. The conductive rings operate as individual electrodes and, in many cases, the leads implanted percutaneously through a large needle is inserted into the epidural space, or without the aid of a stylet.

Our analysis of this patent is as follows:

Nevro Corporation’s patent US 9265935 B2 deals with Neurological stimulation lead anchors and associated systems and methods.
A theme lead anchor consisting of a longitudinally extending arm with an aperture sized and positioned to receive a lead line. A retainer that around the arms and moved to compress at least a portion of the arm against a lead frame that came with the arm. A covering provided around the retainer and includes at least one opening formed through the cover to facilitate participation in retainer with a tool.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.